|
Post by mnkdfann on Oct 11, 2017 22:06:00 GMT -5
Which foundation? So it sounds like part of it is a done deal. " the sale of 166,600 shares issued a foundation in this offering" Who / what are you quoting?
|
|
|
Post by brotherm1 on Oct 11, 2017 22:26:26 GMT -5
10% dilution, 18.48% Pps drop, overdone, shorts piled in. After this Week, Pps might float back to $6. Mnkd can now negotiate in a better position of strength. Next on deck are ER, international expansions, STAT completion 10/15/17. I’m thinking and hoping the recapitalization is still on deck. I’d like to see some debt restructuring. Afterwards as the share price consequently moves up, then perhaps another equity raise, perhaps sale of a pipeliner.....in other words more capital with little or no dilution to get us at least an extra six months of cash and cash to better market and ramp up sales at a faster pace.
|
|
|
Post by straightly on Oct 11, 2017 23:17:50 GMT -5
First, I agree the sell off was overdone, but I think blame can be spread a bit more than is being done by posters. Sure, some shorts were active today, but some may have also taken the opportunity to cover. Don't sell "short" the notion that a significant number of folks who were long on MNKD took profits today. To some, much of the price appreciation now appeared orchestrated to take advantage of the label change catalyst and the ensuing run-up to raise the equity. If I were a $6 buyer of that offering, I wouldn't be pleased. I just hope there's no price adjustment in that offering - those folks can be such big whiners! Yesterday's move was so strong that notwithstanding getting a nice price for that money raise, many decided to sell. And, if nothing else, the many day traders that had been drawn to MNKD like moths to a flame over the last 7 or so trading days, probably either sat on the sidelines when hit with the news, or actually sold short on a short term basis (not our traditional shorts that hang on like barnacles). All this noise will pass soon and more fundamental news will be needed. Baba, I would not worry too much of our $6 buyer(s). Trust me on this, he (they) is doing just fine, thank you. I am counting my blessings for mnkd more than doubled in last few days and I am having opportunity to buy the dip. Onwards and upwards.
|
|
|
Post by afrezzamiracle on Oct 11, 2017 23:35:37 GMT -5
Straightly, whom is the buying party?
|
|
|
Post by lakers on Oct 12, 2017 0:45:12 GMT -5
New Label For Afrezza Could Turn Things Around At MannKind m.benzinga.com/article/10160000?utm_referrer=https%3A%2F%2Fwww.google.com%2FDespite a more than 200-percent gain in MannKind Corporation (NASDAQ: MNKD)'s stock over the past month alone analysts at H.C. Wainwright see even further upside ahead. The firm's Oren Livnat initiates coverage of MannKind's stock with a Buy rating and $7 price target, which represents a gain of more than $1 per share from Tuesday's opening price of $5.89 (see Livnat's track record here). After spending more than $2 billion over two decades developing the only approved inhaled and rapid-acting insulin therapy for diabetes called Afrezza, MannKind went on to secure a "blockbuster" partnership with Sanofi SA (ADR) (NYSE: SNY). However, since then a "disappointing partner launch" resulted in Afrezza being returned in 2016 and the stock plummeted 98 percent from peak to trough. Meanwhile, Wall Street "largely wrote off" Afrezza and MannKind's stock but this perception could change under a new management team and a "game-changing" new label, which was approved last week, the analyst continued. Specifically, Afrezza could gain traction in the "very large" insulin space and prove to be the "significant product that its innovation merits." "We believe Afrezza inhaled insulin is a clearly differentiated meal-time insulin therapy vs. injectable market leaders Novolog and Humalog, which combine for $3.5B in the U.S.," the analyst explained. "Besides the apparent advantages of a more convenient and less stigmatizing puff on an inhaler at meal-time vs. injections, the even greater value of Afrezza is its inherent "faster in, faster out" pharmacodynamics (PD), which more closely mimic endogenous insulin in healthy people. Faster in and out means that it should better control glucose at meal-time and lower risk of delayed hypoglycemia, which is the biggest risk of insulin therapy." Bottom line, MannKind will evolve from being "knocked out to take out" by a larger player as the company accelerates Afrezza's growth and achieve peak sales of more than $725 million in the U.S. At time of publication, shares of MannKind were up 26.08 percent at $6.72.
|
|
|
Post by straightly on Oct 12, 2017 0:51:21 GMT -5
Straightly, whom is the buying party? No idea. I worked for a company that had done some "finance" with prefered stocks, debts, and commons. The buyers, after everything is said and done, for reasons at the time not known or obvious to us, always end up winning. So I am pretty sure that our $6 buyers have today's drop in their calculations and will be fine. I do not know the reason and am only trying to align my position with their moves.
|
|
|
Post by mnholdem on Oct 12, 2017 4:47:12 GMT -5
It's obviously in the interests of hedge fund managers and short pundits, who try to make their living by shorting stock, to spread fear and shake the tree. This time, though, because of minimal dilution and strengthening of the company financials, those who took short positions yesterday may get burned.
|
|
|
Post by patten1962 on Oct 12, 2017 7:00:24 GMT -5
It's obviously in the interests of hedge fund managers and short pundits, who try to make their living by shorting stock, to spread fear and shake the tree. This time, though, because of minimal dilution and strengthening of the company financials, those who took short positions yesterday may get burned. Be nice to see a little jump in scripts tomorrow. May stop the bleeding!
|
|
|
Post by esstan2001 on Oct 12, 2017 7:42:08 GMT -5
It's obviously in the interests of hedge fund managers and short pundits, who try to make their living by shorting stock, to spread fear and shake the tree. This time, though, because of minimal dilution and strengthening of the company financials, those who took short positions yesterday may get burned. Be nice to see a little jump in scripts tomorrow. May stop the bleeding! This isn't bleeding... more like a minor surface abrasion (recalls 'We the Black Knights' who hath suffered many minor flesh wounds of MannKind in thy past)
|
|
|
Post by n8 on Oct 12, 2017 7:43:34 GMT -5
Be nice to see a little jump in scripts tomorrow. May stop the bleeding! This isn't bleeding... more like a minor surface abrasion (recalls 'We the Black Knights' who hath suffered many minor flesh wounds of MannKind in thy past) Its time for mike to throw in the HOLY Hand Grenade.........
|
|
|
Post by patten1962 on Oct 12, 2017 7:55:59 GMT -5
Be nice to see a little jump in scripts tomorrow. May stop the bleeding! This isn't bleeding... more like a minor surface abrasion (recalls 'We the Black Knights' who hath suffered many minor flesh wounds of MannKind in thy past) I love the black Knight.
|
|
|
Post by lakers on Oct 13, 2017 18:48:55 GMT -5
|
|
|
Post by boca1girl on Oct 13, 2017 19:02:16 GMT -5
Starts at 22:50 with Nate.
|
|
|
Post by nylefty on Oct 13, 2017 19:35:42 GMT -5
Starts at 22:50 with Nate. Nate said fair value of MNKD is in the "20 to 30 dollar range," but that it could drop to $3.50 before rising to 9 or 10 dollars. He advises buying small lots on a regular basis. He also said that there's a "real possibility" of a buyout by a big pharma company.
|
|
|
Post by sportsrancho on Oct 13, 2017 20:03:29 GMT -5
Excellent!! Between $20-$30 Other PB getting nervous. Market headed up and bio highlighted.
|
|